We showed that PR5-LL-CM01 was ~10-15 fold more potent than EPZ015666 in PDAC and CRC models, making PR5-LL-CM01 the first PRMT5 inhibitor to be highly effective in the treatment of solid tumors. The gene discussed is PRMT5; the disease is colorectal carcinoma.